SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Henry Niman who wrote (4628)6/30/1998 5:10:00 PM
From: Joe E.   of 6136
 
Henry:
further regarding salvage from protease inhibitor resistance:
healthcg.com

The above is kind of a summary article, and further has this summary paragraph:
"What are we to make of these studies? Together they suggest that it may be possible to sequence protease inhibitors (especially if the primary failure is with nelfinavir) but the odds are greatly improved if the switch is done early (when the viral load is still relatively low, such as below 5,000-10,000 copies/ml). "

I was hoping for more patients in the studies, though.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News